The University of Chicago Header Logo

Connection

Everett Vokes to Antibodies, Bispecific

Back to Details
This is a "connection" page, showing publications Everett Vokes has written about Antibodies, Bispecific.
Everett Vokes
Connection Strength
0.895
Antibodies, Bispecific
  1. LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC. Future Oncol. 2025 Jul; 21(16):2007-2016.
    View in: PubMed
    Score: 0.895
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.